Edgar Filing: Ajer Jeffrey Robert - Form 4

| Ajer Jeffrey Form 4 | | | | | | | | | | | | |
|--|--|--|----------------|---------------------------------|-------------|---------------------------------------|--|------------------------------|---|--|--|--|
| May 03, 201 | | | | | | | | | | | PROVAL | |
| FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | | | | | | | OMB Number: | 3235-0287 | | | |
| Check th if no lon subject t Section Form 4 o Form 5 obligatio may con <i>See</i> Instr 1(b). | ger o 16. or Filed put ons stinue. | Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 | | | | | | | | | January 31, 2005 verage rs per 0.5 | |
| (Print or Type | Responses) | | | | | | | | | | | |
| 1. Name and Address of Reporting Person <u>*</u> Ajer Jeffrey Robert | | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | |
| (Last) (First) (Middle) C/O BIOMARIN PHARMACEUTICAL INC.,, 105 DIGITAL DRIVE | | | | | | | | | Director 10% Owner X Officer (give title Other (specify below) below) SVP, Chief Commercial Of | | | |
| NOVATO, | Filed(Month/Day/Year) | | | | | | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | |
| (City) | (State) | (Zip) | Tah | le I - N | on-I |)erivative | Secu | | ired, Disposed of, | or Reneficial | v Owned | |
| 1.Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | | ed Date, if | 3. Transa Code (Instr. | actio 8) | 4. Securi nor Dispos (Instr. 3, | ties A sed of 4 and (A) or | cquired (A) (D) 5) | 5. Amount of | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of | |
| Common Stock | 04/30/2013(1) | | | Code A | | Amount 797 | (D) A | Price \$ 23.2 | 11,367 | D | | |
| Common Stock | 05/01/2013 <u>(2)</u> | 05/01/20 |)13 | S | | 797 | D | \$ 64.5175 (<u>3)</u> | 10,570 | D | | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

Edgar Filing: Ajer Jeffrey Robert - Form 4

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transactic Code (Instr. 8) | 5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Nu Deriv Secu Bene Own Follo Repo Trans (Instr |
|---|---|---|---|--|---|--|--------------------|---|--|---|---|
| Repo | rting C | wners | | Code V | (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | |

Reporting Owner Name / Address Director 10% Owner

Ajer Jeffrey Robert C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE NOVATO, CA 94949

SVP, Chief Commercial Of

Other

Relationships

Officer

Signatures

/s/ Laura Randall Woodhead, Attorney-in-Fact

**Signature of Reporting Person

Date

05/03/2013

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reporting person is reporting the acquisition of shares of the issuer's Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of November 1, 2012 to April 30, 2013.
- (2) Transaction made pursuant to a Rule 10b5-1 plan executed on December 11, 2012.

The price in column 4 is a weighted average price. The price actually received ranged from \$64.10 to \$65.12. The reporting person will(3) provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.